CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


AnluohuaxianWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1699 Oral Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.12
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study

To evaluate the efficacy and safety of Anluohuaxian in blocking the progression of pulmonary fibrosis and improving lung function in patients with COVID-19.

NCT04334265 COVID-19 Drug: Anluohuaxian
MeSH:Coronavirus Infections Virus Diseases

Primary Outcomes

Description: Changes in ground-glass shadows, interstitial or air nodules found on high-resolution computer tomography

Measure: Changes in high-resolution computer tomography of the lung

Time: 3 months

Measure: Change in 6-minute walking distance

Time: 3 months

Secondary Outcomes

Measure: Changes in compound physiological index

Time: 3 months

Description: St. George's Hospital Respiratory Questionnaire range from 0 to 100. 0 stands for no impact on life and 100 stands for extreme impact on life.

Measure: Changes in the scores of the St. George's Hospital Respiratory Questionnaire

Time: 3 months

Description: mMRC score range from 0 to 4. 0 stands for wheezing only when exercising hard and 4 stands for severe breathing difficulties.

Measure: Changes in modified British Medical Research Council Dyspnea Scale (mMRC) scores

Time: 3 months

Description: Adult male vital capacity is about 3,500 ml and female is about 2,500 ml.

Measure: Changes in vital capacity of the lung

Time: 3 months


No related HPO nodes (Using clinical trials)